Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment

Biochemical Pharmacology

Volumn 80, Issue 1, 2010, Pages 31-38

  Bright, Sandra A ^a   Campiani, Giuseppe ^b   Deininger, Michael W ^c   Lawler, Mark ^d   Williams, D Clive ^a   Zisterer, Daniela M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF SIENA   (Italy)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d ST JAMES S HOSPITAL   (Ireland)

Author keywords

Apoptosis; CML; Flavopiridol; PBOX; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; FLAVOPIRIDOL; IMATINIB; ISOLEUCINE; MUTANT PROTEIN; PYRROLO 1,5 BENZOXAZEPINE; SURVIVIN; THREONINE; TUBULIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DEPOLYMERIZATION; DOWN REGULATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME INACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICROTUBULE; MONOTHERAPY; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLAVONOIDS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICROTUBULE-ASSOCIATED PROTEINS; OXAZEPINES; PIPERAZINES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 77952288488     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.02.019     Document Type: Article

References (47)

1. Druker B., Sawyers C., Capdeville R., Ford J., Baccarani M., Goldman J. Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program 2001, 1:87-112.
2. Kurzrock R., Kantarjian H., Druker B., Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003, 138:819-830.
3. Deininger M., Goldman J., Melo J. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
4. Deininger M., Buchdunger E., Druker B. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
5. Deininger M., Druker B. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003, 55:401-423.
6. O'Hare T., Eide C.A., Deininger M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110:2242-2249.
7. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:99-102.
8. Deep G., Agarwal R. New combination therapies with cell-cycle agents. Curr Opin Investig Drugs 2008, 9:591-604.
9. Zisterer D.M., Campiani G., Nacci V., Williams D.C. Pyrrolo-1,5-benzoxazepines induce apoptosis in HL-60, Jurkat, and Hut-78 cells: a new class of apoptotic agents. J Pharmacol Exp Ther 2000, 293:48-59.
10. Mc Gee M.M., Campiani G., Ramunno A., Fattorusso C., Nacci V., Lawler M., et al. Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl. J Pharmacol Exp Ther 2001, 296:31-40.
11. Mulligan J.M., Greene L.M., Cloonan S., Mc Gee M.M., Onnis V., Campiani G., et al. Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines. Mol Pharmacol 2006, 70:60-70.
12. Mc Gee M.M., Campiani G., Ramunno A., Nacci V., Lawler M., Williams D.C., et al. Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells. J Biol Chem 2002, 277:18383-18389.
13. Mc Gee M.M., Greene L.M., Ledwidge S., Campiani G., Nacci V., Lawler M., et al. Selective induction of apoptosis by the pyrrolo-1,5-benzoxazepine 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in leukemia cells occurs via the c-Jun NH2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-XL. J Pharmacol Exp Ther 2004, 310:1084-1095.
14. McElligott A.M., Maginn E.N., Greene L.M., McGuckin S., Hayat A., Browne P.V., et al. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. Cancer Res 2009, 69:8366-8375.
15. Bright SA, McElligott AM, O'Connell JW, O'Connor L, Carroll P, Campiani G, et al. Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo; 2010 (unpublished results).
16. Greene L.M., Fleeton M., Mulligan J., Gowda C., Sheahan B.J., Atkins G.J., et al. The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status and inhibits breast tumour growth in vivo. Oncol Rep 2005, 14:1357-1363.
17. Greene L.M., Kelly L., Onnis V., Campiani G., Lawler M., Williams D.C., et al. STI-571 enhances the apoptotic efficacy of PBOX-6, a novel microtubule targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells. J Pharmacol Exp Ther 2007, 321:288-297.
18. Senderowicz A.M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 1999, 17:313-320.
19. Shapiro G.I. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 2004, 10:4270-4275.
20. Schwartz G.K., Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005, 23:9408-9421.
21. Aklilu M., Kindler H.L., Donehower R.C., Mani S., Vokes E.E. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003, 14:1270-1273.
22. Stadler W.M., Vogelzang N.J., Amato R., Sosman J., Taber D., Liebowitz D., et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 2000, 18:371-375.
23. Liu G., Gandara D.R., Lara P.N.J., Raghavan D., Doroshow J.H., Twardowski P., et al. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res 2004, 10:924-928.
24. Schwartz G.K., Ilson D., Saltz L., O'Reilly E., Tong W., Maslak P., et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001, 19:1985-1992.
25. Christian B.A., Grever M.R., Byrd J.C., Lin T.S. Flavopiridol in the treatment of chronic lymphocytic leukemia. Curr Opin Oncol 2007, 19:573-578.
26. Phelps M.A., Lin T.S., Johnson A.J., Hurh E., Rozewski D.M., Farley K.L., et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009, 113:2637-2645.
27. Karp J.E., Smith B.D., Levis M.J., Gore S.D., Greer J., Hattenburg C., et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007, 13:4467-4473.
28. Fornier M.N., Rathkopf D., Shah M., Patil S., O'Reilly E., Tse A.N., et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007, 13:5841-5846.
29. Tan A.R., Yang X., Berman A., Zhai S., Sparreboom A., Parr A.L., et al. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 2004, 10:5038-5047.
30. George S., Kasimis B.S., Cogswell J., Schwarzenberger P., Shapiro G.I., Fidias P., et al. Phase I study of flavopiridol in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer. Clin Lung Cancer 2008, 9:160-165.
31. O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A., et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000, 97:13103-13107.
32. Altieri D.C. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 2006, 5:478-482.
33. Bible K.C., Kaufmannm S.H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997, 57:3375-3380.
34. Motwani M., Delohery T.M., Schwartz G.K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999, 7:1876-1883.
35. Motwani M., Li X., Schwartz G.K. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells. Clin Cancer Res 2000, 6:924-932.
36. Wall N.R., O'Connor D.S., Plescia J., Pommier Y., Altieri D.C. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003, 63:230-235.
37. O'Hare T., Eide C.A., Tyner J.W., Corbin A.S., Wong M.J., Buchanan S., et al. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci USA 2008, 105:5507-5512.
38. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
39. Bright S.A., Greene L.M., Greene T.F., Campiani G., Butini S., Brindisi M., et al. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells. Biochem Pharmacol 2009, 77:310-321.
40. Zisterer D.M., McGee M.M., Campiani G., Ramunno A., Fattorusso C., Nacci V., et al. Pyrrolo-1,5-benzoxazepines: a new class of apoptotic agents. Biochem Soc Trans 2001, 29:704-706.
41. Greene L.M., Campiani G., Lawler M., Williams D.C., Zisterer D.M. BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines. Mol Pharmacol 2008, 73:419-430.
42. Ling X., Bernacki R.J., Brattain M.G., Li F. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem 2004, 279:15196-15203.
43. Giaccone G., Zatloukal P., Roubec J., Floor K., Musil J., Kuta M., et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009, 27:4481-4486.
44. Satoh T., Okamoto I., Miyazaki M., Morinaga R., Tsuya A., Hasegawa Y., et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009, 15:3872-3880.
45. Khanna N., Dalby R., Tan M., Arnold S., Stern J., Frazer N. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol Oncol 2007, 107:554-562.
46. Sausville E.A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 2002, 4:S32-S37.
47. Kitada S., Zapata J.M., Andreeff M., Reed J.C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000, 96:393-397.